Roche Holding AG / Constitution Medical Investors Inc.

Hematology Diagnostics (anemia, leukemia, blood disorders)

$2.0B Global hematology testing market 2013 (~$2B)

Disease Overview

Hematology diagnostics covers laboratory testing for blood-based disorders, including complete blood counts (CBCs), white-cell differentials, and morphology review used to diagnose anemia, leukemia, and clotting disorders. CBCs are among the most-ordered lab tests globally; accurate cell classification is workflow-intensive and historically required manual microscopy review on top of automated counters.

Competitive Landscape

The 2013 hematology analyzer market was led by Sysmex (Japan) and Beckman Coulter (US, then a Danaher subsidiary), with Abbott (CELL-DYN) and Siemens (ADVIA) as the principal challengers. Sysmex's Americas hematology revenue jumped roughly 31% in 2013, eroding Beckman's longstanding US lead, while Roche historically distributed Sysmex analyzers under a partnership rather than owning a hematology platform of its own. The Bloodhound deal gave Roche its first proprietary hematology instrument, integrating digital morphology, cell counting, and slide staining in a single device—differentiated from impedance/flow-cytometry incumbents that still required separate slide-makers and offline pathologist review. The acquisition repositioned Roche from a Sysmex distribution partner to a direct competitor, gave it a Boston center of excellence, and signaled intent to push integrated lab solutions tying chemistry, immunoassay, and hematology onto a unified workflow. The strategic risk: launching a brand-new platform against entrenched menus and IT integrations at a moment Sysmex was accelerating US placements.